{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:29:45Z","timestamp":1786422585346,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vancomycin is widely used to treat neonatal late-onset sepsis (LOS). However, its optimal pharmacokinetic\/pharmacodynamic targets in neonates, particularly those with very low birth weight (VLBW), remain inadequately defined. Therefore, the objective of this study is to identify vancomycin exposure thresholds associated with early clinical and microbiologic effectiveness in VLBW neonates with LOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A multicenter observational study included VLBW neonates who received vancomycin for LOS and had at least 1 steady-state trough concentration measured. Based on clinical and microbiological outcomes within the first 72 hours of vancomycin therapy, patients were categorized into 2 groups: early clinical and microbiological cure (ECMC) and late clinical and microbiological cure. Vancomycin exposure threshold predictive of ECMC was identified using classification and regression tree analysis and the receiver operating characteristic curve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-six VLBW neonates with confirmed Gram-positive LOS were included, of whom 27 (75%) achieved ECMC. A significant correlation was observed between area under the curve (AUC)\n                      <jats:sub>24<\/jats:sub>\n                      and trough concentrations (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.568;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Both AUC\n                      <jats:sub>24<\/jats:sub>\n                      and trough concentrations were significantly higher in the ECMC than in the late clinical and microbiological cure group [median (interquartile range), 257 (229\u2013330) vs. 175 (151\u2013223) mg\u00b7h\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005; 10.2 (6.0\u201313.3) vs. 5.1 (3.0\u201310.0) mg\/L;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.043, respectively]. An AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC threshold of \u2265 253\u2009mg.h\/L was identified as the optimal threshold associated with ECMC with better discriminative performance than trough concentrations (AUC-receiver operating characteristic, 0.813 vs. 0.726;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.045, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      While both exposure metrics demonstrated good predictive performance for ECMC in VLBW neonates with LOS, an AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC \u2265253 mg\u00b7h\/L showed superior discriminative performance compared with trough concentrations. Prospective validation of this exposure threshold in larger cohorts is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005369","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:00:20Z","timestamp":1786420820000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Vancomycin Exposure for Early Treatment Response in Very-Low-Birth-Weight Neonates With Late-Onset Sepsis"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-4443","authenticated-orcid":false,"given":"Manal","family":"Abouelkheir","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-6713","authenticated-orcid":false,"given":"Hekmat M.","family":"El Magdoub","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Misr International University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-327X","authenticated-orcid":false,"given":"Zekra K.","family":"Aljehani","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center (Gen. Org), Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-2728","authenticated-orcid":false,"given":"Hessa","family":"Al Muqati","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2818-1048","authenticated-orcid":false,"given":"Dalia Ahmed","family":"Ballal","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Pharmaceutical Care Administration, Armed Forces Hospital, Southern Region, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7920-0916","authenticated-orcid":false,"given":"Abdulmohsen","family":"Assiri","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Pharmaceutical Care Administration, Armed Forces Hospital, Southern Region, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7508-4809","authenticated-orcid":false,"given":"Manea Fares","family":"Al Munjem","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Department, King Khalid Hospital, Najran, Saudi Arabia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-8369","authenticated-orcid":false,"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"R1-20260811","first-page":"e68057","article-title":"Bloodstream infections in the neonatal intensive care unit: a systematic review of the literature.","volume":"16","author":"Vogiantzi","year":"2024","journal-title":"Cureus"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S2213-2600(18)30063-8","article-title":"The global burden of paediatric and neonatal sepsis: a systematic review.","volume":"6","author":"Fleischmann-Struzek","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/archdischild-2020-320217","article-title":"Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis.","volume":"106","author":"Fleischmann","year":"2021","journal-title":"Arch Dis Child"},{"issue":"Suppl 2","key":"R4-20260811","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0378-3782(12)70019-1","article-title":"Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units.","volume":"88","author":"Hornik","year":"2012","journal-title":"Early Hum Dev"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.2147\/IDR.S416020","article-title":"Prevalence of multidrug-resistant pathogens causing neonatal early and late onset sepsis, a retrospective study from the tertiary referral children\u2019s hospital.","volume":"16","author":"Fang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/antibiotics11020284","article-title":"Early and late onset neonatal sepsis: epidemiology and effectiveness of empirical antibacterial therapy in a III level neonatal intensive care unit.","volume":"11","author":"Mariani","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jiac.2016.11.009","article-title":"Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.","volume":"23","author":"Kato","year":"2017","journal-title":"J Infect Chemother"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"e02523","DOI":"10.1128\/AAC.02523-20","article-title":"Population pharmacokinetic analysis and dose regimen optimization in Japanese infants with an extremely low birth weight.","volume":"65","author":"Sasano","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pedneo.2022.10.006","article-title":"Evaluation of vancomycin individualized model-based dosing approach in neonates.","volume":"64","author":"Abouelkheir","year":"2023","journal-title":"Pediatr Neonatol"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"1093171","DOI":"10.3389\/fped.2023.1093171","article-title":"Population pharmacokinetics of vancomycin in very low birth weight neonates.","volume":"11","author":"Alsultan","year":"2023","journal-title":"Front Pediatr"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R13-20260811","first-page":"99","article-title":"Empiric vancomycin dosing in neonates: relationship between initial dose and 24\u2009h area under the curve\/minimum inhibitory concentration ratio.","volume":"37","author":"Klahn","year":"2020","journal-title":"Rev Chilena Infectol"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12887-016-0753-0","article-title":"Coagulase-negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?","volume":"16","author":"Padari","year":"2016","journal-title":"BMC Pediatr"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/FTD.0000000000000216","article-title":"Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration \u2265400 target.","volume":"37","author":"Bhongsatiern","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1542\/peds.2014-3819","article-title":"Neonatal acute kidney injury.","volume":"136","author":"Selewski","year":"2015","journal-title":"Pediatrics"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/NPM-15814103","article-title":"Comparison of intermittent versus continuous vancomycin infusion for the treatment of late-onset sepsis in preterm infants.","volume":"8","author":"Demirel","year":"2015","journal-title":"J Neonatal Perinatal Med"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"e0110922","DOI":"10.1128\/aac.01109-22","article-title":"Association between vancomycin pharmacokinetic parameters and clinical and microbiological efficacy in a cohort of neonatal patients.","volume":"66","author":"Mej\u00edas-Trueba","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pedneo.2021.11.010","article-title":"Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: a retrospective study based on electronic medical records.","volume":"63","author":"Chen","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"106300","DOI":"10.1016\/j.ijantimicag.2021.106300","article-title":"Determination of vancomycin exposure target and individualized dosing recommendations for neonates: model-informed precision dosing.","volume":"57","author":"Tang","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/jac\/dkae374","article-title":"Identification of vancomycin exposure target in neonates: how much is enough?","volume":"79","author":"Gao","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s10096-018-3277-8","article-title":"Factors impacting unbound vancomycin concentrations in neonates and young infants.","volume":"37","author":"Smits","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/21505594.2017.1419117","article-title":"Beyond sepsis: staphylococcus epidermidis is an underestimated but significant contributor to neonatal morbidity.","volume":"9","author":"Dong","year":"2018","journal-title":"Virulence"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1136\/archdischild-2014-306213","article-title":"Late-onset neonatal sepsis: recent developments.","volume":"100","author":"Dong","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"F547","DOI":"10.1136\/archdischild-2017-313203","article-title":"Epidemiology of UK neonatal infections: the neonIN infection surveillance network.","volume":"103","author":"Cailes","year":"2018","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"e0227823","DOI":"10.1371\/journal.pone.0227823","article-title":"Staphylococcus epidermidis in feedings and feces of preterm neonates.","volume":"15","author":"Moles","year":"2020","journal-title":"PLoS One"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jiph.2019.03.007","article-title":"Characteristics of neonatal sepsis at a tertiary care hospital in Saudi Arabia.","volume":"12","author":"Al-Matary","year":"2019","journal-title":"J Infect Public Health"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3201\/eid2303.160833","article-title":"Worldwide endemicity of a multidrug-resistant staphylococcus capitis clone involved in neonatal sepsis.","volume":"23","author":"Butin","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/antibiotics12040669","article-title":"Staphylococcus capitis: review of its role in infections and outbreaks.","volume":"12","author":"Heath","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/archdischild-2023-325887","article-title":"Clinical outcomes of Staphylococcus capitis isolation from neonates, England, 2015-2021: a retrospective case-control study.","volume":"109","author":"Yuan","year":"2024","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"106515","DOI":"10.1016\/j.ijantimicag.2021.106515","article-title":"Dosing of vancomycin and target attainment in neonates: a systematic review.","volume":"59","author":"Alrahahleh","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"R34-20260811","first-page":"83","article-title":"Optimization of vancomycin dosing in very low-birth-weight preterm neonates.","volume":"32","author":"Madigan","year":"2015","journal-title":"Am J Perinatol"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12887-017-0777-0","article-title":"The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit.","volume":"17","author":"Bhargava","year":"2017","journal-title":"BMC Pediatr"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41372-019-0519-2","article-title":"Vancomycin drug monitoring in infants with CoNS sepsis: target attainment, microbiological response, and nephrotoxicity.","volume":"40","author":"Viel-Th\u00e9riault","year":"2020","journal-title":"J Perinatol"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ejhpharm-2019-002181","article-title":"Assessment of initial vancomycin trough levels and risk factors of vancomycin-induced nephrotoxicity in neonates.","volume":"29","author":"Dawoud","year":"2022","journal-title":"Eur J Hosp Pharm"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:00:25Z","timestamp":1786420825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005369","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}